• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form FWP filed by HCA Healthcare Inc.

    2/18/25 8:41:14 PM ET
    $HCA
    Hospital/Nursing Management
    Health Care
    Get the next $HCA alert in real time by email
    FWP 1 d910031dfwp.htm FWP FWP

    Filed pursuant to Rule 433

    Issuer Free Writing Prospectus, dated February 18, 2025

    Supplementing the Preliminary Prospectus Supplement, dated February 18, 2025

    Registration No. 333-271537

    HCA Inc.

    $700,000,000 5.000% Senior Notes due 2028 (the “2028 notes”)

    $300,000,000 Floating Rate Senior Notes due 2028 (the “floating rate notes”)

    $750,000,000 5.250% Senior Notes due 2030 (the “2030 notes”)

    $750,000,000 5.500% Senior Notes due 2032 (the “2032 notes”)

    $1,500,000,000 5.750% Senior Notes due 2035 (the “2035 notes”)

    $1,250,000,000 6.200% Senior Notes due 2055 (the “2055 notes”)

    (collectively, the “notes”)

    Pricing Supplement

    Pricing Supplement dated February 18, 2025 to HCA Inc.’s Preliminary Prospectus Supplement dated February 18, 2025. This Pricing Supplement is qualified in its entirety by reference to the Preliminary Prospectus Supplement. The information in this Pricing Supplement supplements the Preliminary Prospectus Supplement and supersedes the information in the Preliminary Prospectus Supplement to the extent it is inconsistent with the information in the Preliminary Prospectus Supplement. Financial information presented in the Preliminary Prospectus Supplement is deemed to have changed to the extent affected by changes described herein. Capitalized terms used in this Pricing Supplement but not defined have the meanings given them in the Preliminary Prospectus Supplement.

     

    Terms Applicable to the 2028 notes
    Issuer    HCA Inc.
    Aggregate Principal Amount    $700,000,000
    Title of Security    5.000% Senior Notes due 2028
    Maturity Date    March 1, 2028
    Spread to Treasury    +70 basis points
    Benchmark Treasury    UST 4.250% due February 15, 2028
    Benchmark Treasury Price & Yield    99-25 3⁄8 / 4.324%
    Coupon    5.000%

     


    Public Offering Price    99.932% of the principal amount plus accrued interest, if any, from February 21, 2025
    Yield to Maturity    5.024%
    Interest Payment Dates    March 1 and September 1 of each year, beginning on September 1, 2025
    Record Dates    February 15 and August 15 of each year
    Net Proceeds to Issuer before Expenses    $696,374,000
    CUSIP/ISIN Numbers   

    CUSIP: 404119 CY3

    ISIN: US404119CY34

    Optional Redemption   

    Prior to February 1, 2028 (the “2028 Notes Par Call Date”), the 2028 notes will be redeemable, at our option, in whole or in part, at any time and from time to time, at a redemption price (expressed as a percentage of principal amount and rounded to three decimal places) equal to the greater of:

     

    (i) (a) the sum of the present values of the remaining scheduled payments of principal and interest thereon discounted to the redemption date (assuming the 2028 notes to be redeemed matured on the 2028 Notes Par Call Date) on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate plus 15 basis points, less (b) interest accrued to the date of redemption, and

     

    (ii)  100% of the aggregate principal amount of the 2028 notes to be redeemed,

     

    plus, in each of clauses (i) and (ii) above, accrued and unpaid interest, if any, to such redemption date.

     

    On and after the 2028 Notes Par Call Date, the 2028 notes will be redeemable, at our option, in whole or in part, at any time and from time to time, at an applicable redemption price equal to 100% of the principal amount of each 2028 note to be redeemed plus accrued and unpaid interest on the 2028 notes to be redeemed to, but not including, the date of redemption.

    Terms Applicable to the floating rate notes
    Issuer    HCA Inc.
    Aggregate Principal Amount    $300,000,000
    Title of Security    Floating Rate Senior Notes due 2028
    Maturity Date    March 1, 2028
    Spread    +87 basis points

     

    -2-


    Base Rate    Compounded SOFR (as determined in accordance with the provisions set forth in the Preliminary Prospectus Supplement)
    Public Offering Price    100.000% of the principal amount plus accrued interest, if any, from February 21, 2025
    Interest Payment Dates    March 1, June 1, September 1 and December 1 of each year, beginning on June 1, 2025
    Interest Periods    Quarterly. The initial period will be the period from, and including the Settlement Date to, but excluding, June 1, 2025, the initial Interest Payment Date. The subsequent interest periods will be the periods from, and including the applicable Interest Payment Date to, but excluding, the next Interest Payment Date or the Maturity Date, as applicable.
    Interest Determination Dates    Two U.S. Government Securities Business Days (as defined in the Preliminary Prospectus Supplement) preceding each Interest Payment Date or the Maturity Date, as applicable.
    Record Dates    February 15, May 15, August 15 and November 15 of each year
    Day Count Convention    Actual / 360
    Optional Redemption    N/A
    Net Proceeds to Issuer before Expenses    $298,650,000
    CUSIP/ISIN Numbers   

    CUSIP: 404119 CX5

    ISIN: US404119CX50

    Terms Applicable to the 2030 notes
    Issuer    HCA Inc.
    Aggregate Principal Amount    $750,000,000
    Title of Security    5.250% Senior Notes due 2030
    Maturity Date    March 1, 2030
    Spread to Treasury    +90 basis points
    Benchmark Treasury    UST 4.250% due January 31, 2030
    Benchmark Treasury Price & Yield    99-10 3⁄4 / 4.400%
    Coupon    5.250%
    Public Offering Price    99.780% of the principal amount plus accrued interest, if any, from February 21, 2025

     

    -3-


    Yield to Maturity    5.300%
    Interest Payment Dates    March 1 and September 1 of each year, beginning on September 1, 2025
    Record Dates    February 15 and August 15 of each year
    Net Proceeds to Issuer before Expenses    $743,850,000
    CUSIP/ISIN Numbers   

    CUSIP: 404119 CZ0

    ISIN: US404119CZ09

    Optional Redemption   

    Prior to February 1, 2030 (the “2030 Notes Par Call Date”), the 2030 notes will be redeemable, at our option, in whole or in part, at any time and from time to time, at a redemption price (expressed as a percentage of principal amount and rounded to three decimal places) equal to the greater of:

     

    (iii)  (a) the sum of the present values of the remaining scheduled payments of principal and interest thereon discounted to the redemption date (assuming the 2030 notes to be redeemed matured on the 2030 Notes Par Call Date) on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate plus 15 basis points, less (b) interest accrued to the date of redemption, and

     

    (iv) 100% of the aggregate principal amount of the 2030 notes to be redeemed,

     

    plus, in each of clauses (i) and (ii) above, accrued and unpaid interest, if any, to such redemption date.

     

    On and after the 2030 Notes Par Call Date, the 2030 notes will be redeemable, at our option, in whole or in part, at any time and from time to time, at an applicable redemption price equal to 100% of the principal amount of each 2030 note to be redeemed plus accrued and unpaid interest on the 2030 notes to be redeemed to, but not including, the date of redemption.

    Terms Applicable to the 2032 notes
    Issuer    HCA Inc.
    Aggregate Principal Amount    $750,000,000
    Title of Security    5.500% Senior Notes due 2032
    Maturity Date    March 1, 2032
    Spread to Treasury    +103 basis points
    Benchmark Treasury    UST 4.375% due January 31, 2032

     

    -4-


    Benchmark Treasury Price & Yield    99-11+ / 4.483%
    Coupon    5.500%
    Public Offering Price    99.923% of the principal amount plus accrued interest, if any, from February 21, 2025
    Yield to Maturity    5.513%
    Interest Payment Dates    March 1 and September 1 of each year, beginning on September 1, 2025
    Record Dates    February 15 and August 15 of each year
    Net Proceeds to Issuer before Expenses    $744,735,000
    CUSIP/ISIN Numbers   

    CUSIP: 404119 DA4

    ISIN: US404119DA49

    Optional Redemption   

    Prior to January 1, 2032 (the “2032 Notes Par Call Date”), the 2032 notes will be redeemable, at our option, in whole or in part, at any time and from time to time, at a redemption price (expressed as a percentage of principal amount and rounded to three decimal places) equal to the greater of:

     

    (i) (a) the sum of the present values of the remaining scheduled payments of principal and interest thereon discounted to the redemption date (assuming the 2032 notes to be redeemed matured on the 2032 Notes Par Call Date) on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate plus 20 basis points, less (b) interest accrued to the date of redemption, and

     

    (ii)  100% of the aggregate principal amount of the 2032 notes to be redeemed,

     

    plus, in each of clauses (i) and (ii) above, accrued and unpaid interest, if any, to such redemption date.

     

    On and after the 2032 Notes Par Call Date, the 2032 notes will be redeemable, at our option, in whole or in part, at any time and from time to time, at an applicable redemption price equal to 100% of the principal amount of each 2032 note to be redeemed plus accrued and unpaid interest on the 2032 notes to be redeemed to, but not including, the date of redemption.

    Terms Applicable to the 2035 notes
    Issuer    HCA Inc.
    Aggregate Principal Amount    $1,500,000,000
    Title of Security    5.750% Senior Notes due 2035

     

    -5-


    Maturity Date    March 1, 2035
    Spread to Treasury    +123 basis points
    Benchmark Treasury    UST 4.625% due February 15, 2035
    Benchmark Treasury Price & Yield    100-18+ / 4.552%
    Coupon    5.750%
    Public Offering Price    99.757% of the principal amount plus accrued interest, if any, from February 21, 2025
    Yield to Maturity    5.782%
    Interest Payment Dates    March 1 and September 1 of each year, beginning on September 1, 2025
    Record Dates    February 15 and August 15 of each year
    Net Proceeds to Issuer before Expenses    $1,486,605,000
    CUSIP/ISIN Numbers   

    CUSIP: 404119 DB2

    ISIN: US404119DB22

    Optional Redemption   

    Prior to December 1, 2034 (the “2035 Notes Par Call Date”), the 2035 notes will be redeemable, at our option, in whole or in part, at any time and from time to time, at a redemption price (expressed as a percentage of principal amount and rounded to three decimal places) equal to the greater of:

     

    (i) (a) the sum of the present values of the remaining scheduled payments of principal and interest thereon discounted to the redemption date (assuming the 2035 notes to be redeemed matured on the 2035 Notes Par Call Date) on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate plus 20 basis points, less (b) interest accrued to the date of redemption, and

     

    (ii)  100% of the aggregate principal amount of the 2035 notes to be redeemed,

     

    plus, in each of clauses (i) and (ii) above, accrued and unpaid interest, if any, to such redemption date.

     

    On and after the 2035 Notes Par Call Date, the 2035 notes will be redeemable, at our option, in whole or in part, at any time and from time to time, at an applicable redemption price equal to 100% of the principal amount of each 2035 note to be redeemed plus accrued and unpaid interest on the 2035 notes to be redeemed to, but not including, the date of redemption.

     

    -6-


    Terms Applicable to the 2055 notes

     

    Issuer    HCA Inc.
    Aggregate Principal Amount    $1,250,000,000
    Title of Security    6.200% Senior Notes due 2055
    Maturity Date    March 1, 2055
    Spread to Treasury    +148 basis points
    Benchmark Treasury    UST 4.500% due November 15, 2054
    Benchmark Treasury Price & Yield    95-18 / 4.781%
    Coupon    6.200%
    Public Offering Price    99.176% of the principal amount plus accrued interest, if any, from February 21, 2025
    Yield to Maturity    6.261%
    Interest Payment Dates    March 1 and September 1 of each year, beginning on September 1, 2025
    Record Dates    February 15 and August 15 of each year
    Net Proceeds to Issuer before Expenses    $1,228,762,500
    CUSIP/ISIN Numbers   

    CUSIP: 404119 DC0

    ISIN: US404119DC05

    Optional Redemption   

    Prior to September 1, 2054 (the “2055 Notes Par Call Date”), the 2055 notes will be redeemable, at our option, in whole or in part, at any time and from time to time, at a redemption price (expressed as a percentage of principal amount and rounded to three decimal places) equal to the greater of:

     

    (iii)  (a) the sum of the present values of the remaining scheduled payments of principal and interest thereon discounted to the redemption date (assuming the 2055 notes to be redeemed matured on the 2055 Notes Par Call Date) on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate plus 25 basis points, less (b) interest accrued to the date of redemption, and

     

    (iv) 100% of the aggregate principal amount of the 2055 notes to be redeemed,

     

    plus, in each of clauses (i) and (ii) above, accrued and unpaid interest, if any, to such redemption date.

     

    On and after the 2055 Notes Par Call Date, the 2055 notes will be redeemable, at our option, in whole or in part, at any time and from time to time, at an applicable redemption price equal to 100% of the principal amount of each 2055 note to be redeemed plus accrued and unpaid interest on the 2055 notes to be redeemed to, but not including, the date of redemption.

     

    -7-


    Terms Applicable to the notes
    Change of Control    Upon a Change of Control Triggering Event, each Holder may require the Issuer to repurchase at 101%, plus accrued and unpaid interest, if any.
    Trade Date    February 18, 2025

    Total Net Proceeds to Issuer before

    Expenses

       $5,198,976,500
    Denominations    $2,000 and integral multiples of $1,000
    Form of Offering    SEC Registered (Registration No. 333-271537)
    Joint Book-Running Managers   

    BofA Securities, Inc.

    Barclays Capital Inc.

    Citigroup Global Markets Inc.

    J.P. Morgan Securities LLC

    Mizuho Securities USA LLC

    Wells Fargo Securities, LLC

    BNP Paribas Securities Corp.

    Capital One Securities, Inc.

    Credit Agricole Securities (USA) Inc.

    Fifth Third Securities, Inc.

    Goldman Sachs & Co. LLC

    Morgan Stanley & Co. LLC

    PNC Capital Markets LLC

    RBC Capital Markets, LLC

    SMBC Nikko Securities Americas, Inc.

    Truist Securities, Inc.

    Co-Managers   

    BBVA Securities Inc.

    CIBC World Markets Corp.

    DNB Markets, Inc.

    Huntington Securities, Inc.

    NatWest Markets Securities Inc.

    Regions Securities LLC

    Scotia Capital (USA) Inc.

    TD Securities (USA) LLC

    Settlement Date   

    February 21, 2025 (T+3)

     

    We expect that delivery of the notes will be made to investors on or about February 21, 2025, which will be the third business day following the date of this pricing term sheet (such settlement being referred to as “T+3”). Under Rule 15c6-1 under the Exchange Act, trades in the secondary market are required to settle in one business day, unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade notes more than one business day prior to the delivery of the notes hereunder will be required, by virtue of the fact that the notes initially settle in T+3, to specify an alternate settlement arrangement at the time of any such trade to prevent a failed settlement. Purchasers of the notes who wish to trade the notes prior to their date of delivery hereunder should consult their advisors.

     

    -8-


     

    The Issuer has filed a registration statement (including a prospectus and a related preliminary prospectus supplement) with the United States Securities and Exchange Commission (“SEC”) for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement, the preliminary prospectus supplement and other documents HCA Healthcare, Inc. has filed with the SEC for more complete information about the Issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, copies of the preliminary prospectus supplement and accompanying prospectus may be obtained from BofA Securities, Inc., NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001, Attn: Prospectus Department, by telephone 1-800-294-1322 or by emailing: [email protected]; Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, [email protected] or by telephone at 1-888-603-5847; Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone: 1-800-831-9146 or by emailing: [email protected]; J.P. Morgan Securities LLC, 383 Madison Avenue, New York, NY 10179, Attention: Investment Grade Syndicate Desk, 3rd Floor, telephone collect at 1-212-834-4533; Mizuho Securities USA LLC, toll free at 1-866-271-7403; or Wells Fargo Securities, LLC, 608 2nd Avenue South, Suite 1000, Minneapolis, MN 55402, Attn: WFS Customer Service, by telephone (toll-free): 1-800-645-3751 or by emailing: [email protected].

    This communication should be read in conjunction with the preliminary prospectus supplement and the accompanying prospectus. The information in this communication supersedes the information in the preliminary prospectus supplement and the accompanying prospectus to the extent inconsistent with the information in such preliminary prospectus supplement and the accompanying prospectus.

    ANY DISCLAIMERS OR OTHER NOTICES THAT MAY APPEAR BELOW ARE NOT APPLICABLE TO THIS COMMUNICATION AND SHOULD BE DISREGARDED. SUCH DISCLAIMERS OR OTHER NOTICES WERE AUTOMATICALLY GENERATED AS A RESULT OF THIS COMMUNICATION BEING SENT VIA BLOOMBERG OR ANOTHER EMAIL SYSTEM.

     

    -9-

    Get the next $HCA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HCA

    DatePrice TargetRatingAnalyst
    4/15/2025$336.00Outperform → Neutral
    Robert W. Baird
    12/17/2024$380.00Neutral
    Analyst
    11/25/2024$400.00 → $320.00Equal Weight → Underweight
    Wells Fargo
    11/22/2024Outperform → Mkt Perform
    Raymond James
    10/11/2024$475.00Overweight
    KeyBanc Capital Markets
    9/3/2024$427.00Equal-Weight
    Morgan Stanley
    5/30/2024$396.00Outperform
    Robert W. Baird
    3/6/2024$356.00Overweight
    Barclays
    More analyst ratings

    $HCA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by HCA Healthcare Inc. (Amendment)

      SC 13G/A - HCA Healthcare, Inc. (0000860730) (Subject)

      2/14/24 5:10:03 PM ET
      $HCA
      Hospital/Nursing Management
      Health Care
    • SEC Form SC 13G/A filed by HCA Healthcare Inc. (Amendment)

      SC 13G/A - HCA Healthcare, Inc. (0000860730) (Subject)

      2/14/24 5:06:57 PM ET
      $HCA
      Hospital/Nursing Management
      Health Care
    • SEC Form SC 13G/A filed by HCA Healthcare Inc. (Amendment)

      SC 13G/A - HCA Healthcare, Inc. (0000860730) (Subject)

      2/13/24 5:06:27 PM ET
      $HCA
      Hospital/Nursing Management
      Health Care

    $HCA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $HCA
    Financials

    Live finance-specific insights

    See more
    • EVP and CFO Marks Mike A gifted 935 shares, received a gift of 647 shares, disposed of $203,529 worth of shares (573 units at $355.20) and acquired $203,529 worth of shares (573 units at $355.20), closing all direct ownership in the company (SEC Form 4)

      4 - HCA Healthcare, Inc. (0000860730) (Issuer)

      5/8/25 6:40:51 PM ET
      $HCA
      Hospital/Nursing Management
      Health Care
    • Director Frist William R was granted 1,026 shares and acquired $3,577,854 worth of shares (10,505 units at $340.60), increasing direct ownership by 9% to 12,931 units (SEC Form 4)

      4 - HCA Healthcare, Inc. (0000860730) (Issuer)

      5/1/25 7:30:55 PM ET
      $HCA
      Hospital/Nursing Management
      Health Care
    • Director Frist Thomas F Iii was granted 1,320 shares, increasing direct ownership by 10% to 14,817 units (SEC Form 4)

      4 - HCA Healthcare, Inc. (0000860730) (Issuer)

      5/1/25 6:49:02 PM ET
      $HCA
      Hospital/Nursing Management
      Health Care
    • HCA Healthcare Reports First Quarter 2025 Results

      HCA Healthcare, Inc. (NYSE:HCA) today announced financial and operating results for the first quarter ended March 31, 2025. Key first quarter metrics (all percentage changes compare 1Q 2025 to 1Q 2024 unless otherwise noted): Revenues totaled $18.321 billion Net income attributable to HCA Healthcare, Inc. totaled $1.610 billion, or $6.45 per diluted share Adjusted EBITDA totaled $3.733 billion Cash flows from operating activities totaled $1.651 billion Same facility admissions increased 2.6 percent and same facility equivalent admissions increased 2.8 percent "The solid fundamentals we saw in our business the past several quarters continued into the first quarter of 2025," said

      4/25/25 7:30:00 AM ET
      $HCA
      Hospital/Nursing Management
      Health Care
    • HCA Healthcare, Inc. 1st Quarter 2025 Earnings Conference Call

      HCA Healthcare, Inc. (NYSE:HCA) announces the following Webcast: What: HCA Healthcare, Inc. 1Q 2025 Earnings Call When: Friday, April 25, 2025 at 9:00 AM Central (10:00 AM Eastern) How: Live Audio over the Internet: https://investor.hcahealthcare.com/events-and-presentations/default.aspx Contact: Frank Morgan, 615-344-2688, Vice President, Investor Relations, [email protected] If you are unable to listen during the live webcast, the call will be archived on the web site: https://investor.hcahealthcare.com/events-and-presentations/default.aspx. View source version on businesswire.com: https://www.businesswire.com/news/home/20250404757460/en/ INVESTOR CONTACT: Frank Morgan

      4/4/25 4:00:00 PM ET
      $HCA
      Hospital/Nursing Management
      Health Care
    • HCA Healthcare Reports Fourth Quarter 2024 Results and Provides 2025 Guidance

      HCA Healthcare, Inc. (NYSE:HCA) today announced financial and operating results for the fourth quarter ended December 31, 2024. Key fourth quarter metrics (all percentage changes compare 4Q 2024 to 4Q 2023 unless otherwise noted): Revenues totaled $18.285 billion Net income attributable to HCA Healthcare, Inc. totaled $1.438 billion, or $5.63 per diluted share (which includes an estimated $0.60 per diluted share unfavorable impact from Hurricanes Helene and Milton) Adjusted EBITDA totaled $3.712 billion Cash flows from operating activities totaled $2.559 billion Same facility admissions increased 3.0 percent and same facility equivalent admissions increased 3.1 percent "

      1/24/25 7:30:00 AM ET
      $HCA
      Hospital/Nursing Management
      Health Care

    $HCA
    SEC Filings

    See more
    • SEC Form 10-Q filed by HCA Healthcare Inc.

      10-Q - HCA Healthcare, Inc. (0000860730) (Filer)

      5/1/25 4:30:20 PM ET
      $HCA
      Hospital/Nursing Management
      Health Care
    • HCA Healthcare Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - HCA Healthcare, Inc. (0000860730) (Filer)

      4/29/25 4:39:03 PM ET
      $HCA
      Hospital/Nursing Management
      Health Care
    • HCA Healthcare Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - HCA Healthcare, Inc. (0000860730) (Filer)

      4/25/25 7:48:16 AM ET
      $HCA
      Hospital/Nursing Management
      Health Care

    $HCA
    Leadership Updates

    Live Leadership Updates

    See more

    $HCA
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $HCA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HCA Healthcare Announces HCA Healthcare Foundation's Support of Girl Scouts Mental Wellness Patch Programs

      HCA Healthcare, Inc. (NYSE:HCA), one of the nation's leading healthcare providers, today announced that the HCA Healthcare Foundation has helped Girl Scouts of the USA (GSUSA) launch a new series of Mental Wellness Patch Programs to address mental wellness among girls in 4th through 12th grade. This is a result of the HCA Healthcare Foundation's $1.38 million grant to GSUSA, through its Healthier Tomorrow Fund, which was announced last year. "The HCA Healthcare Foundation has a long history of partnering with Girl Scouts nationally and locally. We are proud to deepen our partnership with Girl Scouts on this research-based mental wellness program," said Joanne Pulles, vice president of com

      9/19/23 8:30:00 AM ET
      $HCA
      Hospital/Nursing Management
      Health Care
    • HCA Healthcare Appoints Jyric Sims President of Company's West Florida Division

      HCA Healthcare, Inc. (NYSE:HCA) today announced Jyric Sims, Ph.D., will become president of the company's West Florida Division, effective June 12. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230420005364/en/Jyric Sims, Ph.D. (Photo: Business Wire) Sims, who currently is CEO of HCA Healthcare's Medical City Plano and Medical City Frisco hospitals, will succeed Ravi Chari, M.D., who recently announced he will retire after 15 years with the company to pursue opportunities in early-stage healthcare companies. A more than 20-year healthcare veteran, Sims has been with HCA Healthcare since 2011. He has served as chief executive

      4/20/23 8:30:00 AM ET
      $HCA
      Hospital/Nursing Management
      Health Care
    • HCA Healthcare Announces Retirement of Longtime Senior Executive Chuck Hall

      HCA Healthcare, Inc. (NYSE:HCA), one of the nation's leading healthcare providers, today announced that Chuck Hall, HCA Healthcare's National Group president, will retire at the end of the year after nearly 36 years with the organization. Currently, Hall is responsible for HCA Healthcare's operations at 96 hospitals across 13 states. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220817005233/en/HCA Healthcare Announces Retirement of Longtime Senior Executive Chuck Hall (Photo: Business Wire) Over more than three decades, Hall has been influential in many successful initiatives that will benefit the company for years to come, inc

      8/17/22 8:30:00 AM ET
      $HCA
      Hospital/Nursing Management
      Health Care
    • HCA Healthcare, Inc. to Present at May Healthcare Conference

      HCA Healthcare, Inc. (NYSE:HCA) is scheduled to present at the following healthcare conferences: May 13, 2025 at 9:20am PT at the Bank of America 2025 Healthcare Conference. A link to the live audio webcast, where applicable, and copies of any related presentation materials will be made available at the Investor Relations section of the Company's website, www.hcahealthcare.com. Dates and times may be subject to change, please check the conference schedule or the Investor Relations section of the Company's website for the latest information. About HCA Healthcare Nashville-based HCA Healthcare is one of the nation's leading providers of healthcare services comprising 192 hospitals and ap

      5/5/25 4:30:00 PM ET
      $HCA
      Hospital/Nursing Management
      Health Care
    • HCA Healthcare Reports First Quarter 2025 Results

      HCA Healthcare, Inc. (NYSE:HCA) today announced financial and operating results for the first quarter ended March 31, 2025. Key first quarter metrics (all percentage changes compare 1Q 2025 to 1Q 2024 unless otherwise noted): Revenues totaled $18.321 billion Net income attributable to HCA Healthcare, Inc. totaled $1.610 billion, or $6.45 per diluted share Adjusted EBITDA totaled $3.733 billion Cash flows from operating activities totaled $1.651 billion Same facility admissions increased 2.6 percent and same facility equivalent admissions increased 2.8 percent "The solid fundamentals we saw in our business the past several quarters continued into the first quarter of 2025," said

      4/25/25 7:30:00 AM ET
      $HCA
      Hospital/Nursing Management
      Health Care
    • Two Large Clinical Trials Find a Highly Effective Method to Select Appropriate Antibiotics for Patients Hospitalized With Abdominal or Skin and Soft Tissue Infection

      Computerized alerts tailored to each patient help identify which antibiotic is best suited to treat patients hospitalized with common infections in two 92-hospital trials. Two large multi-state studies funded by the National Institutes of Health and led by the University of California, Irvine, Harvard Pilgrim Health Care Institute, and HCA Healthcare have found a highly effective method to improve antibiotic selection for patients who are hospitalized with abdominal or skin and soft tissue infection to reduce their risk of antibiotic resistance. Results were published in JAMA Surgery and JAMA Internal Medicine and highlighted at the Congress of the European Society of Clinical Microbiology

      4/10/25 1:00:00 PM ET
      $HCA
      Hospital/Nursing Management
      Health Care
    • HCA downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded HCA from Outperform to Neutral and set a new price target of $336.00

      4/15/25 9:26:09 AM ET
      $HCA
      Hospital/Nursing Management
      Health Care
    • Analyst resumed coverage on HCA with a new price target

      Analyst resumed coverage of HCA with a rating of Neutral and set a new price target of $380.00

      12/17/24 8:04:06 AM ET
      $HCA
      Hospital/Nursing Management
      Health Care
    • HCA downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded HCA from Equal Weight to Underweight and set a new price target of $320.00 from $400.00 previously

      11/25/24 7:44:35 AM ET
      $HCA
      Hospital/Nursing Management
      Health Care

    $HCA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Bank Of America Corp /De/ bought $88,208 worth of shares (3,436 units at $25.67) and sold $79,816 worth of shares (3,178 units at $25.12) (SEC Form 4)

      4 - HCA Healthcare, Inc. (0000860730) (Issuer)

      3/28/25 4:11:57 PM ET
      $HCA
      Hospital/Nursing Management
      Health Care